

Supplementary Table 2. Detailed wording for symptoms used in VAS across different studies

Scale	Wording	Reference
	Mouth	
Oral dryness	0 indicated no symptom/activity and 100 mm the greatest possible symptom severity/activity	1
	0 indicated the absence of clinical symptoms, and a score of 10 indicated unbearable clinical symptoms	2
	0 for the total absence of symptom to 100 for worst imaginable symptom	3
	“Not troublesome” (0 mm) and “extremely troublesome” (100 mm)	4–6
	How dry does your mouth feel most of the time? (not dry at all, 0 mm; dry as a desert, 100 mm)	7
	0 mm = extremely dry, to 100 mm =not dry at all	8
	mean of 12 items related to oral and throat dryness, each rated 0–100	9
	Dry mouth, difficulty chewing due to dry mouth, difficult swallowing due to dry mouth, difficulty speaking due to dry mouth, taste alteration/decrease, burning sensation, difficulty in denture retention due to dry mouth	10
	Mouth dryness, desire to sip water when eating a meal, difficulty in speaking, difficulty chewing, difficulty tasting, difficulty swallowing food	11
	Continuous dry mouth, burning tongue, painful oral mucosa, diminished taste, difficulty in mastication, difficulty in swallowing, need to sip liquids to aid swallowing, difficulty in speaking, dryness at night or awakening, frequent need to moisten oral mucosa	12
	Mouth dryness, discomfort of the mouth, ability to sleep, ability to speak without drinking liquids, ability to chew and swallow food, ability to wear dentures	13
	dry mouth, burning oral mucosa, difficulty in mastication, need to sip liquids during swallowing, frequent need to moisten oral mucosa	14
	<i>Wording not specified</i>	15–23
Mouth discomfort	How much discomfort do you feel in your mouth? (no discomfort, 0 mm; worst possible discomfort, 100 mm)	7

Scale	Wording	Reference
Salivary gland swelling	0 indicated the absence of clinical symptoms, and a score of 10 indicated unbearable clinical symptoms	2
Difficulty swallowing	0 for the total absence of symptom to 100 for worst imaginable symptom	3
Tracheal dryness	<i>Wording not specified</i>	18, 22, 23
Eyes		
Dryness	0 indicated no symptom/activity and 100 mm the greatest possible symptom severity/activity	1
	0 indicated the absence of clinical symptoms, and a score of 10 indicated unbearable clinical symptoms	2
	A range from 0 for the total absence of symptom to 100 for worst imaginable symptom	3
	0 for no symptoms to 100 for extreme symptoms	24
	“Not troublesome” (0 mm) and “extremely troublesome” (100 mm) for dry eyes, feeling of sand/gravel in eyes	4
	“Not troublesome” (0 mm) and “extremely troublesome” (100 mm)	5
	“On average, how troublesome was the feeling of dry eyes in the last 2 days,” and, “On average, how troublesome was the feeling of gritty eyes in the last 2 days.” Scale: 0, not troublesome, to 100 mm, extremely troublesome	25
	How dry do your eyes feel most of the time (not dry at all, 0 mm; very dry, 100 mm)?	7
	Scale 0 to 10: 0 = “not dry at all” and 10 = “as dry as the desert”	26
	0 mm = extremely dry, to 100 mm = not dry at all	8
Sum of 2 items related to eye dryness, each rated 0–100	9	
	<i>Wording not specified</i>	15–23
Ocular discomfort	0 mm represented minimal symptoms and 100 mm represented maximal symptoms	27

Scale	Wording	Reference
Eyeball pain	<i>Wording not specified</i>	15
Skin		
Dryness	0 indicated no symptom/activity and 100 mm the greatest possible symptom severity/activity <i>Wording not specified</i>	1 18, 22, 23
Vagina		
Dryness	0 indicated no symptom/activity and 100 mm the greatest possible symptom severity/activity <i>Wording not specified</i>	1 18, 22, 23
General		
Dryness	Scores range from 0 (none) to 100 mm (worst) 0 indicated absence of the symptom (or inactive disease) and 100 the greatest severity possible <i>Wording not specified</i>	28 29 30–33
Sicca syndrome	<i>Wording not specified</i>	22
Global		
Health	Scores range from 0 (none) to 100 mm (worst) 0 as no problem and 100 as worst 0 absence of the symptom (or inactive disease) and 100 the greatest severity possible Very good, 0 mm; very bad, 100 mm <i>Wording not specified</i>	28 34 29 9, 35 36
Fatigue		
Fatigue	0 indicated no symptom/activity and 100 mm the greatest possible symptom severity/activity 0 indicated absence of the symptom (or inactive disease) and 100 the greatest severity possible A range from 0 for the total absence of symptom to 100 for worst imaginable symptom 0 for no symptoms to 100 for extreme symptoms	1 29 3 24

Scale	Wording	Reference
	Scores range from 0 (none) to 100 mm (worst)	28
	0 mm was “No fatigue” and 100 mm was “Fatigue as bad as it can be”	37
	“How have you experienced fatigue during last week?”	19
	Anchors were 0 mm = tiredness is no problem, and 100 mm = tiredness is a big problem	
	“Fatigue is no problem” to “Fatigue is a major problem”	38
	0 as no problem and 100 as worst	34
	Ranging from 0 for absence of fatigue to 100 for worst imaginable fatigue	39
	0 = no fatigue and 100 = most severe fatigue	18
	0 as “not fatigued at all” and 100 as “extremely fatigued”	40
	0 mm = extreme fatigue and 100 mm = no fatigue at all	8
	not at all tired, 0 mm; very tired, 100 mm	35
	<i>Wording not specified</i>	16, 17, 22, 23, 30–33, 41–44, 47
Pain		
General	Scores range from 0 (none) to 100 mm (worst)	28
	0 as no problem and 100 as worst	34
	Not at all, 0 mm; worst possible, 100 mm	7, 35
	“No pain” and “Pain as bad as it could be”	38
	“No pain” (0 mm) and “the most pain ever” (100 mm)	5
	0, not troublesome, to 100 mm, extremely troublesome	25
	0 indicated absence of the symptom (or inactive disease) and 100 the greatest severity possible	29
	<i>Wording not specified</i>	22, 23, 31, 32, 36, 42, 45, 46
Arthralgia	0 for the total absence of symptom to 100 for worst imaginable symptom	3
	0 for no symptoms to 100 for extreme symptoms	24
	<i>Wording not specified</i>	17

Scale	Wording	Reference
Myalgia	0 for the total absence of symptom to 100 for worst imaginable symptom	3
	<i>Wording not specified</i>	17
Limb pain	0 indicated no symptom/activity and 100 mm the greatest possible symptom severity/activity	1
Musculo-skeletal	Mean of scores for 2 items: joint pain and muscle pain	9
	<i>Wording not specified</i>	30, 3
Eyeball	<i>Wording not specified</i>	15
Parotid	<i>Wording not specified</i>	21
Central nervous system		
Sleep	0 as no problem and 100 as worst	34
Depression	<i>Wording not specified</i>	17
Anxiety	<i>Wording not specified</i>	15, 17
Stress	<i>Wording not specified</i>	9

SUPPLEMENTAL REFERENCES

1. Cornec D, Devauchelle-Pensec V, Mariette X, *et al.* Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. *Rheumatology (Oxford)* 2015;**54**:1699–708.
2. Shi H, Zheng LY, Zhang P, *et al.* miR-146a and miR-155 expression in PBMCs from patients with Sjögren's syndrome. *J Oral Pathol Med* 2014;**43**:792–7.
3. Seitsalo H, Niemelä RK, Marinescu-Gava M, *et al.* Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sjögren's syndrome: a randomized, double-blind, placebo controlled cross-over study. *J Negat Results Biomed* 2007;**6**:11.
4. van Leeuwen N, Bossema ER, van Middendorp H, *et al.* Dealing with emotions when the ability to cry is hampered: emotion processing and regulation in patients with primary Sjögren's syndrome. *Clin Exp Rheumatol* 2012;**30**:492–8.
5. Hartkamp A, Geenen R, Godaert GL, *et al.* Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial. *Ann Rheum Dis* 2008;**67**:91–7.
6. Seror R, Ravaud P, Bowman SJ, *et al.*; EULAR Sjögren's Task Force. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. *Ann Rheum Dis* 2010;**69**:1103–9. Erratum in: *Ann Rheum Dis* 2011;**70**:880.
7. Forsblad-d'Elia H, Carlsten H, Labrie F, *et al.* Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. *J Clin Endocrinol Metab* 2009;**94**:2044–51.
8. Theander E, Andersson SI, Manthorpe R, *et al.* Proposed core set of outcome measures in patients with primary Sjögren's syndrome: 5 year follow up. *J Rheumatol* 2005;**32**:1495–502.
9. Segal BM, Pogatchnik B, Henn L, *et al.* Pain severity and neuropathic pain symptoms in primary Sjögren's syndrome: a comparison study of seropositive and seronegative Sjögren's syndrome patients. *Arthritis Care Res (Hoboken)* 2013;**65**:1291–8.
10. Aliko A, Alushi A, Tafaj A, *et al.* Evaluation of the clinical efficacy of Biotène Oral Balance in patients with secondary Sjögren's syndrome: a pilot study. *Rheumatol Int* 2012;**32**:2877–81.
11. Kasama T, Shiozawa F, Isozaki T, *et al.* Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren's syndrome. *Mod Rheumatol* 2008;**18**:455–9.

12. Alpöz E, Güneri P, Onder G, *et al.* The efficacy of Xialine in patients with Sjögren's syndrome: a single-blind, cross-over study. *Clin Oral Investig* 2008;**12**:165–72.
13. Wu CH, Hsieh SC, Lee KL, *et al.* Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial. *J Formos Med Assoc* 2006;**105**:796–803.
14. Cankaya H, Alpöz E, Karabulut G, *et al.* Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2010;**110**:62–7.
15. Hur J, Chung SW, Ha YJ, *et al.* Association between insomnia and EULAR Sjögren's syndrome patient-reported index in Korean patients with primary Sjögren's syndrome. *ACR Poster Session A*. 2015; abstract 639.
16. Hammenfors DS, Brun JG, Jonsson R, *et al.* Diagnostic utility of major salivary gland ultrasonography in primary Sjögren's syndrome. *Clin Exp Rheumatol* 2015;**33**:56–62.
17. Cho HJ, Yoo JJ, Yun CY, *et al.* The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients. *Rheumatology (Oxford)* 2013;**52**:2208–17.
18. Ibn Yacoub Y, Rostom S, Laatiris A, *et al.* Primary Sjögren's syndrome in Moroccan patients: characteristics, fatigue and quality of life. *Rheumatol Int* 2012;**32**:2637–43.
19. Haldorsen K, Bjelland I, Bolstad AI, *et al.* A five-year prospective study of fatigue in primary Sjögren's syndrome. *Arthritis Res Ther* 2011;**13**:R167.
20. Meijer JM, Meiners PM, Vissink A, *et al.* Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2010;**62**:960–8.
21. Nakayamada S, Saito K, Umehara H, *et al.* Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. *Mod Rheumatol* 2007;**17**:464–9.
22. Devauchelle-Pensec V, Pennec Y, Morvan J, *et al.* Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). *Arthritis Rheum* 2007;**57**:310–17.
23. Champey J, Corruble E, Gottenberg JE, *et al.* Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features. *Arthritis Rheum* 2006;**55**:451–7.
24. Willeke P, Schlüter B, Becker H, *et al.* Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. *Arthritis Res Ther* 2007;**9**:R115.

25. Vriezekolk JE, Geenen R, Hartkamp A, *et al.* Psychological and somatic predictors of perceived and measured ocular dryness of patients with primary Sjögren's syndrome. *J Rheumatol* 2005;**32**:2351–5.
26. Caffery B, Joyce E, Boone A, *et al.* Tear lipocalin and lysozyme in Sjögren and non-Sjögren dry eye. *Optom Vis Sci* 2008;**85**:661–7.
27. Tuisku IS, Konttinen YT, Konttinen LM, *et al.* Alterations in corneal sensitivity and nerve morphology in patients with primary Sjögren's syndrome. *Exp Eye Res* 2008;**86**:879–85.
28. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, *et al.* Treatment of primary Sjögren syndrome with rituximab: a randomized trial. *Ann Intern Med* 2014;**160**:233–42.
29. Devauchelle-Pensec V, Morvan J, Rat AC, *et al.* Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome. *Clin Exp Rheumatol* 2011;**29**:6–12.
30. Mariette X, Seror R, Quartuccio L, *et al.* Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. *Ann Rheum Dis* 2015;**74**:526–31.
31. Carubbi F, Cipriani P, Marrelli A, *et al.* Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. *Arthritis Res Ther* 2013;**15**:R172.
32. Gottenberg JE, Seror R, Benessiano J, *et al.* Is fatigue immune-mediated in primary Sjögren's syndrome? Data from the Prospective assess cohort. *Ann Rheum Dis* 2015;**74 Suppl 2**:796.
33. De Vita S, Quartuccio L, Seror R, *et al.* Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the Beliss open-label phase II study. *Ann Rheum Dis* 2015;**74 Suppl 2**:338–9.
34. George A, Pope JE. The minimally important difference (MID) for patient-reported outcomes including pain, fatigue, sleep and the health assessment questionnaire disability index (HAQ-DI) in primary Sjögren's syndrome. *Clin Exp Rheumatol* 2011;**29**:248–53.
35. d'Elia HF, Rehnberg E, Kvist G, *et al.* Fatigue and blood pressure in primary Sjögren's syndrome. *Scand J Rheumatol* 2008;**37**:284–92.
36. Kedor C, Hagemann A, Zernicke J, *et al.* Effectiveness and safety of low-dose cyclosporine a in patients with primary Sjögren's syndrome (pSS) with articular involvement – results of a pilot study. *Ann Rheum Dis* 2015;**74 Suppl. 2**:341.
37. Norheim KB, Harboe E, Gøransson LG, *et al.* Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome – a double blind, randomised clinical trial. *PLoS One* 2012;**7**:e30123.

38. Segal B, Thomas W, Rogers T, *et al.* Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren's syndrome. *Arthritis Rheum* 2008;**59**:1780–7.
39. Dass S, Bowman SJ, Vital EM, *et al.* Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. *Ann Rheum Dis* 2008;**67**:1541–4.
40. Strömbeck BE, Theander E, Jacobsson LT. Effects of exercise on aerobic capacity and fatigue in women with primary Sjögren's syndrome. *Rheumatology (Oxford)* 2007;**46**:868–71.
41. Tjensvoll AB, Harboe E, Gøransson LG, *et al.* Headache in primary Sjögren's syndrome: a population-based retrospective cohort study. *Eur J Neurol* 2013;**20**:558–63.
42. Iannuccelli C, Spinelli FR, Guzzo MP, *et al.* Fatigue and widespread pain in systemic lupus erythematosus and Sjögren's syndrome: symptoms of the inflammatory disease or associated fibromyalgia? *Clin Exp Rheumatol* 2012;**30**(6 Suppl 74):117–21.
43. Theander L, Strömbeck B, Mandl T, *et al.* Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary Sjögren's syndrome? *Rheumatology (Oxford)* 2010;**49**:1177–83.
44. Harboe E, Tjensvoll AB, Vefring HK, *et al.* Fatigue in primary Sjögren's syndrome--a link to sickness behaviour in animals? *Brain Behav Immun* 2009;**23**:1104–8.
45. Pertovaara M, Korpela M. ESSPRI and other patient-reported indices in patients with primary Sjögren's syndrome during 100 consecutive outpatient visits at one rheumatological clinic. *Rheumatology (Oxford)* 2014;**53**:927–31.
46. Hackett KL, Newton JL, Frith J, *et al.* Impaired functional status in primary Sjögren's syndrome. *Arthritis Care Res (Hoboken)* 2012;**64**:1760–4.
47. Theander E, Henriksson G, Ljungberg O, *et al.* Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. *Ann Rheum Dis* 2006;**65**:796–803.